Trials / Recruiting
RecruitingNCT06405230
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
A Pilot/Exploratory Translational Study to Evaluate Response to Dostarlimab and Pembrolizumab in Extracellular Vesicles (EVs) or Patient-derived Organoids (PDOs) and by Zirconium-89 Labelled Programmed Death Ligand 1 Positron Emission Tomography in Participants With Recurrent Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced/metastatic stages.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pembrolizumab | Pembrolizumab will be administered. |
| BIOLOGICAL | Dostarlimab | Dostarlimab will be administered. |
| DRUG | Pemetrexed+ (carboplatin or cisplatin) | PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered. |
Timeline
- Start date
- 2025-12-30
- Primary completion
- 2028-08-07
- Completion
- 2029-10-10
- First posted
- 2024-05-08
- Last updated
- 2026-02-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT06405230. Inclusion in this directory is not an endorsement.